Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
|
|
- Brent Harvey
- 5 years ago
- Views:
Transcription
1 The Oncologist Mayo Clinic Hematology/Oncology Reviews Is There a Preferred Combination Chemotherapy Regimen for Metastastic Non-Small Cell Lung Cancer? DAVID S. ETTINGER Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA Key Words. Metastatic non-small cell lung cancer Combination chemotherapy Phase III studies LEARNING OBJECTIVES After completing this course, the reader will be able to: 1. Choose the appropriate chemotherapeutic regimen to treat a patient with metastatic non-small cell lung cancer. 2. Identify the advantages and disadvantages of the various regimens to treat stage IV non-small cell cancer. 3. Understand the toxicities associated with each of the various chemotherapeutic regimens. CME ABSTRACT Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Since over 70% of patients with non-small cell lung cancer (NSCLC) have advanced (locally advanced or metastatic) disease, the majority of NSCLC patients might benefit from chemotherapy. During the past decade, a number of new agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan) have been found to be effective against lung cancer. These agents have been combined with cisplatin, carboplatin, and nonplatinum drugs to treat NSCLC. They, in general, produce median survival times of 8-10 months and 1- and 2-year survival rates of 35%-40% and 10%- 15%, respectively. Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose. The Oncologist 2002;7: INTRODUCTION It is estimated that there will be 169,400 (90,200 male and 79,200 female) new cases of lung cancer diagnosed in 2002 with approximately 154,900 deaths (89,200 male and 65,700 female) [1]. Unfortunately, only 14% of all lung cancer patients (all stages) will be alive 5 or more years after their diagnosis [2]. Over 70% of lung cancer patients, when diagnosed, have advanced (locally advanced or metastatic) disease. There is an obvious need for systemic chemotherapy since the majority of non-small cell lung cancer (NSCLC) tumors are inoperable at diagnosis, and patients treated with surgery and or radiation therapy develop distant metastases. During the last 10 years, a number of new agents were found to be effective against lung cancer (Table 1). They have all been incorporated in a number of combination Correspondence: David S. Ettinger, M.D., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room G88, 1650 Orleans Street, Baltimore, Maryland , USA. Telephone: ; Fax: ; ettinda@jhmi.edu Received December 5, 2001; accepted for publication January 23, AlphaMed Press /2002/$5.00/0 The Oncologist 2002;7:
2 227 Is There a Preferred Combination Chemotherapy Regimen for Metastastic NSCLC? Table 1. Classes of new agents active in lung cancer Mode of action Antimetabolite Antitubulins-classical Antitubulins- stabilizing Topoisomerase-1 inhibitors Agent(s) Gemcitabine Vinorelbine Paclitaxel, docetaxel Irinotecan, topotecan chemotherapeutic regimens, many of which included either cisplatin or carboplatin to treat patients with NSCLC. The use of chemotherapy in the treatment of metastatic NSCLC is palliative in nature. The benefits of therapy for stage IV NSCLC are to: A) cause an objective tumor response; B) decrease symptoms; C) improve quality of life, and D) improve survival. The risks associated with chemotherapy are: A) toxicities associated with therapy; B) treatment-related deaths; C) increased costs and inconvenience of treatment, and D) increased hospitalization time. This article addresses the question: Is there a preferred combination chemotherapy regimen for metastatic NSCLC? It only includes data from phase III trials; however, not every phase III study is mentioned. In my opinion, the question can be answered without including every phase II or III study evaluating various chemotherapy regimens to treat metastatic NSCLC. INITIAL ECOG AND SWOG STUDIES In 1993, both the Eastern Cooperative Oncology Group (ECOG) and the Southwest Oncology Group (SWOG) initiated phase III studies evaluating two of the new drugs against NSCLC [3, 4]. In the ECOG study, stage IIIB/IV NSCLC patients were randomized to receive either paclitaxel plus cisplatin or etoposide plus cisplatin [3]. Paclitaxel was given i.v. over 24 hours as either a 135 mg/m 2 or 250 mg/m 2 dose, while etoposide was administered at 100 mg/m 2 i.v. daily on days 1-3. Each drug was administered with cisplatin given at 75 mg/m 2 i.v. on day 1. The therapy was repeated every 21 days. G-CSF was administered with the high-dose paclitaxel regimen. Five hundred and ninety-nine patients were entered in the trial. The objective response rates for the low-dose and high-dose paclitaxel regimens and for the etoposide plus cisplatin therapy were 25.3%, 27.7%, and 12.4%, respectively. The two paclitaxel regimens combined gave a superior survival time compared with the etoposide plus cisplatin regimen. The median survival times and 1-year survival rates were 9.9 months and 38% versus 7.6 months and 31.8% (p = 0.048), respectively. There was no survival difference between the two paclitaxel regimens. Toxicities were similar in the three arms, except for a greater incidence of granulocytopenia with the low-dose paclitaxel, and greater incidences of myalgias, neurotoxicity, and possible cardiac toxicity with the high-dose paclitaxel. Based on this study, low-dose paclitaxel (135 mg/m 2 ) plus cisplatin replaced etoposide plus cisplatin as the reference regimen for future ECOG studies. In the SWOG study, 432 patients with stage IIIB/IV NSCLC were randomized to receive either the single agent cisplatin, 100 mg/m 2 i.v. every 4 weeks, or cisplatin, 100 mg/m 2 i.v. every 4 weeks, plus vinorelbine, 25 mg/m 2 i.v. weekly [4]. For the single-agent therapy versus the combination regimen, the response rates were 12% versus 26% (p = ), the overall median survival times were 6 months versus 8 months (p = ), the 1-year survival rates were 20% versus 36%, and the 2-year survival rates were 6% versus 12%. The two-drug regimen had an 81% occurrence of grade 3/4 granulocytopenia versus 5% with the single agent, cisplatin. Based on this study, vinorelbine plus cisplatin became the new standard for SWOG advanced NSCLC studies. FOLLOW-UP ECOG AND SWOG STUDIES ECOG, after doing the above study, randomized 1,207 NSCLC patients to four different combination chemotherapy regimens: paclitaxel plus cisplatin (their standard ), docetaxel plus cisplatin, gemcitabine plus cisplatin, and paclitaxel plus carboplatin (Table 2) [5]. Eighty-five percent of the patients had metastatic disease. The objective response rates varied from 15.3% to 21.3%. The median survival ranged from 7.4 months to 8.2 months with 1- and 2-year survival rates varying from 31% to 36% and 10.5% to 15.7%, respectively. The differences in the above rates among the four regimens were not statistically significant. However, the time to progression (TTP) was significant, in favor of the gemcitabine plus cisplatin regimen. In part, this improvement in TTP may be explained by the fact that patients receiving gemcitabine plus cisplatin were evaluated every 4 weeks rather than every 3 weeks, as with the other regimens in the study. The paclitaxel plus carboplatin treatment was reasonably well tolerated except for a higher rate of neuropathy, while the gemcitabine plus cisplatin regimen was associated with more renal toxicity, anemia, and thrombocytopenia. The ECOG study did not identify a superior regimen that would be recommended as the standard therapy for patients with metastatic NSCLC. However, many of the ECOG NSCLC studies that followed utilized the paclitaxel plus carboplatin regimen. SWOG conducted a phase III trial comparing a cisplatin plus vinorelbine treatment regimen with a paclitaxel plus carboplatin treatment regimen in patients with stage IIIB/IV NSCLC (Table 3) [7]. For these regimens, only 12% and 11% of patients, respectively, had stage IIIB disease. Four hundred and eight patients were eligible for the
3 Ettinger 228 Table 2. Eastern Cooperative Oncology Group study 1594 Drugs T Cis Gem Cis Tax Cis T Carbo Entered Eligible Median survival (mo) year survival (%) year survival (%) OR (%) TTP (mo) * Toxicities renal hypersens. grade 4/5 toxicities anemia neut. fever thrombocytopenia neuropathy neut. fever *p = T Cis = paclitaxel, 135 mg/m 2 i.v. over 24 hours, day 1; cisplatin, 75 mg/m 2 i.v., day 2 every 3 weeks Gem Cis = gemcitabine, 1,000 mg/m 2, days 1, 8, and 15; cisplatin, 100 mg/m 2, day 1 every 4 weeks Tax Cis = docetaxel, 75 mg/m 2 over 1 hour, day 1; cisplatin, 75 mg/m 2 i.v., day 1 every 3 weeks T Carbo = paclitaxel, 225 mg/m 2 i.v. over 3 hours, day 1; carboplatin (AUC 6.0), day 1 every 3 weeks Abbreviations: AUC = area under the concentration time curve; OR = overall response; TTP = time to progression Table 3. Southwest Oncology Group study PC Vino/Cis n of patients Response (%) Median survival (mo) year survival (%) Grade 4 neutropenia p < 0.05 Grade 3 nausea 6 17 p < 0.01 Grade 3 neuropathy 8 3 p < 0.05 Completed study p < 0.05 Off study due to toxicity (%) p < 0.01 PC = paclitaxel, 225 mg/m 2 over 3 hours, day 1; carboplatin, AUC = 6, day 1 every 21 days. Vino/Cis = vinorelbine, 25 mg/m 2 i.v., weekly; cisplatin, 100 mg/m 2 i.v, day 1 every 28 days. GEMCITABINE/CISPLATIN VERSUS ETOPOSIDE/CISPLATIN After a gemcitabine plus cisplatin versus cisplatin alone randomized trial in stage IIIB/IV NSCLC gave a statistically significant survival advantage for the combination [7], another phase III study compared that combination with etoposide plus cisplatin (Table 4) [8]. One hundred and thirty-five NSCLC patients were entered in the study, 133 of whom were included in the intent-to-treat analysis of response. In this study, 47.8% of patients receiving gemcitabine-cisplatin had stage IIIB disease while 51.5% of the patients receiving etoposide-cisplatin had stage IIIB disease. NSCLC patients receiving gemcitabine-cisplatin had a statistically significant higher response rate (40.6% versus 21.9%; p = 0.02) and TTP (6.9 months versus 4.3 months; p = 0.01) than patients receiving etoposide-cisplatin. study, and of these, 365 were evaluable. There were similar response rates (27%) and median survival times (8 months) in the two treatment groups. The 1- and 2-year survival rates were 38% and 15%, respectively, for the paclitaxel regimen and 36% and 16%, respectively, for the vinorelbine combination. The incidences of hematologic toxicity and nausea were higher on the vinorelbine plus cisplatin therapy, while the incidence of peripheral neuropathy was higher on the paclitaxel plus carboplatin regimen. More NSCLC patients receiving vinorelbine plus cisplatin were unable to complete the therapy due to toxicity. The investigators concluded that both regimens were effective in the treatment of advanced NSCLC, however, their future standard was to be paclitaxel plus carboplatin due to the lower toxicity and better tolerability of the regimen. Table 4. Gemcitabine/cisplatin versus etoposide/cisplatin in stage IIIB and IV NSCLC Gem/Cis E/Cis n of patients Response (%) p = 0.02 Median survival (mo) p = 0.18 TTP (mo) p = Grade 3/4 toxicity (%) Neutropenia 36/28 20/56 Thrombocytopenia 39/16 8/5 Nausea and vomiting 35/4 19/7 Alopecia 13/ 51/ Gem/Cis = gemcitabine, 1,250 mg/m 2 i.v., days 1 and 8; cisplatin, 100 mg/m 2 i.v., day 1 every 21 days. E/Cis = etoposide, 100 mg/m 2 i.v., days 1-3; cisplatin, 100 mg/m 2 i.v., day 1 every 21 days.
4 229 Is There a Preferred Combination Chemotherapy Regimen for Metastastic NSCLC? Unfortunately, there was no statistically significant difference in survival time between the regimens (8.7 months versus 7.2 months, p = 0.18). Nausea and vomiting as well as thrombocytopenia were more frequent with the gemcitabine regimen, while alopecia was markedly less with the combination. There were no thrombocytopenia-related complications associated with the gemcitabine-cisplatin regimen. The gemcitabine-cisplatin regimen, although not significantly improving survival times, did provide a significantly higher response rate and TTP without significantly affecting the quality of life in stage IIIB/IV NSCLC patients. HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY In 1998, the Hellenic Cooperative Oncology Group initiated a phase III study comparing gemcitabine/paclitaxel with carboplatin/paclitaxel in patients with advanced NSCLC (Table 5) [9]. Eligible patients had inoperable stage IIIA, IIIB, or IV NSCLC. There was no statistically significant difference between the two regimens in the treatment of advanced NSCLC in regard to response rate, TTP, median survival, 1-year survival, or toxicity, although the response rate, survival time, and 1-year survival rate were superior for the noncisplatin-containing regimen gemcitabine plus paclitaxel. It should be noted that, although patients receiving either regimen were reported to be well matched with baseline demographics and patient characteristics, no mention was made regarding what percentage of patients had stage IIIA/IIIB disease. EORTC LUNG STUDY The European Organization for Research and Treatment of Cancer (EORTC) lung cancer group performed a randomized phase III trial of three chemotherapy regimens (paclitaxel/cisplatin, gemcitabine/cisplatin, and paclitaxel/gemcitabine) in advanced NSCLC (Table 6) [10]. Four hundred and eighty patients were entered in the trial. Only 21% of all patients had stage IIIB disease, while 79% had stage IV disease. The noncisplatin regimen paclitaxel/gemcitabine had a lower response rate, survival time, and 1- year survival rate than the two cisplatin-containing regimens in the treatment of advanced NSCLC. The regimens were reasonably well tolerated, although there was more thrombocytopenia with the gemcitabine/cisplatin treatment than with the other two regimens. ITALIAN LUNG CANCER TRIAL Six hundred and twelve patients with stage IIIB/IV NSCLC, 81% of whom had stage IV disease, were entered in a phase III randomized study comparing three platinumbased doublets (Table 7) [11]. The response rates (60%-63%) and median survival times (9.5 months to 9.9 months) were Table 5. Hellenic Oncology Group study Gemcitabine/ Carboplatin/ paclitaxel* paclitaxel** p value n of patients entered Grade 3/4 neutropenia (%) Grade 3/4 thrombocytopenia (%) Grade 3/4 anemia (%) Grade 3/4 neurotoxicity (%) Number of patients evaluated Complete + partial responses (%) Median time to tumor progression (mo) Median survival (mo) year survival (%) **Gemcitabine = 1 g/m 2, days 1 and 8, paclitaxel, 200 mg/m 2 over 3 hours, day 1 **every 21 days. **Carboplatin = AUC 6, day 1, paclitaxel, 200 mg/m 2 over 3 hours, day 1 every **21 days. Table 6. European Organization for Research and Treatment of Cancer study (08975) Pac/Cis* Gem/Cis** Pac/Gem*** n of patients Grade 3/4 neutropenia (%) Grade 3/4 thrombocytopenia (%) Toxic deaths Response rate (%) Median survival (mo) year survival (%) ***Paclitaxel = 175 mg/m 2 over 3 hours, day 1, cisplatin, 80 mg/m 2, day 1 over 21 days. ***Gemcitabine = 1,250 mg/m 2, days 1 and 8, cisplatin, 80 mg/m 2, day 1 over 21 days. ***Paclitaxel = 175 mg/m 2 over 3 hours, day 1, gemcitabine, 1,250 mg/m 2, days 1 ***and 8 over 21 days. similar among the three regimens. There were greater incidences of grade 3/4 neutropenia and alopecia with the paclitaxel/carboplatin than with either of the two cisplatincontaining regimens. However, there was more peripheral neuropathy associated with the noncisplatin-containing regimen paclitaxel/carboplatin. DOCETAXEL STUDY TAX 326 The Tax 326 phase III study compared two docetaxelcontaining regimens with a regimen of vinorelbine and cisplatin in NSCLC patients with stage IIIB/IV disease (Table 8) [12]. The percentage of patients with stage IIIB disease ranged from 31% to 34%. The three regimens were similar in toxicity except there were higher incidences of anemia and vomiting associated with the vinorelbine/cisplatin regimen. The response rate was not reported. The median survival, 1- year survival, and 2-year survival rates were higher for the
5 Ettinger 230 Table 7. Italian lung cancer trial Cis/Gem* Pac/Carbo** Cis/Vino*** Grade 3/4 neutropenia (%) Grade 3/4 thrombocytopenia (%) 16 3 <1 Grade 3/4 anemia (%) Alopecia (%) Peripheral neuropathy ( grade 2) (%) Nausea and vomiting (%) Response rate (%) Median survival (mo) ***Cisplatin = 75 mg/m 2, day 2, gemcitabine, 1,250 mg/m 2, days 1 and 8 every ***3 weeks. ***Paclitaxel = 225 mg/m 2 over 3 hours, carboplatin, AUC = 6 every 3 weeks. ***Cisplatin = 100 mg/m 2, day 1, vinorelbine 25 mg/m 2, weekly every 4 weeks. Table 8. Docetaxel study Tax 326 DC* D Carbo** VC*** n of patients Stage IV (%) Grade 3/4 anemia (%) Grade 3/4 neutropenia (%) Grade 3/4 vomiting (%) p < 0.01 Grade 3/4 neurosensory Response rate NR NR NR Median survival (mo) year survival (%) year survival (%) ***DC = docetaxel, 75 mg/m 2 over 1 hour, cisplatin, 75 mg/m 2 every 21 days. ***D Carbo = docetaxel, 75 mg/m 2 over 1 hour, carboplatin, AUC = 6 every ***21 days. ***VC = vinorelbine, 25 mg/m 2, weekly, cisplatin, 100 mg/m 2 every 28 days. docetaxel/cisplatin combination, however, these were not statistically significant. Table 9. National Coalition of Cooperative Groups study Gemcitabine 1,000 mg/m 2, days 1 and 8 Carboplatin AUC = 5.5, day 1 every 21 days Gemcitabine 1,000 mg/m 2, days 1 and 8 Paclitaxel 200 mg/m 2 over 3 hours, day 1 every 21 days Paclitaxel 225 mg/m 2 over 3 hours, day 1 Carboplatin AUC = 6, day 1 every 21 days Table 10. Cancer and Leukemia Group B study Paclitaxel 200 mg/m 2 over 3 hours, day 1 every 21 days Paclitaxel 200 mg/m 2 over 3 hours, day 1 every 21 days Carboplatin AUC = 6, day 1 Table 11. CPT-11 Lung Cancer Study Group trial CPT-11/Cis VDS/Cis Grade 3/4 neutropenia (%) Grade 3/4 diarrhea (%) 13 1 Response rate (%) Median survival (weeks) For stage IV patients only Median survival (mo) year survival (%) year survival (%) 9 10 CPT-11/Cis = irinotecan, 60 mg/m 2 i.v., days 1, 8, and 15; cisplatin, 80 mg/m 2 i.v., day 1 every 4 weeks. VDS/Cis = vindesine 3 mg/m 2 i.v., days 1, 8, and 15; cisplatin 80 mg/m 2 i.v., day 1 every 4 weeks. (Table 10). The results of the study will be presented at the American Society of Clinical Oncology meeting in May of NATIONAL COALITION OF COOPERATIVE GROUPS STUDY The National Coalition of Cooperative Groups is conducting a phase III study in stage IIIB/IV NSCLC patients that compares gemcitabine/carboplatin treatment with gemcitabine/paclitaxel and with paclitaxel/carboplatin treatments (Table 9). The plan is to enter 300 patients in each arm. The end points include survival, quality-of-life measurements, and toxicity. CALGB STUDY The Cancer and Leukemia Group B (CALGB) has completed a phase III randomized study comparing single-agent paclitaxel therapy with a paclitaxel plus carboplatin regimen CPT-11 LUNG CANCER STUDY GROUP TRIAL In Japan, a randomized multicenter phase III trial was done comparing irinotecan/cisplatin treatment with vindesine/cisplatin treatment (Table 11) [13]. Two hundred and ten advanced NSCLC patients were entered into the trial. Forty-one percent of patients had stage IIIB disease. For the irinotecan/cisplatin regimen, the response rate was 29%, median survival was 45.4 weeks, and toxicities (grade 3 or higher) included neutropenia (63%) and diarrhea 13%; for the vindesine/cisplatin regimen, the response rate was 22%, median survival was 49.6 weeks, and toxicities (grade 3 or higher) included neutropenia (83%) and diarrhea (1%). The new regimen of irinotecan/cisplatin appears as active as the standard regimen of vindesine/cisplatin.
6 231 Is There a Preferred Combination Chemotherapy Regimen for Metastastic NSCLC? Table 12. Second CPT-11 Lung Cancer Study Group trial CPT-11/Cis VDS/Cis CPT-11 Grade 4 neutropenia (%) Grade 3 diarrhea (%) Response rate (%) Median survival (weeks) year survival (%) For stage IV patients only Median survival (mo) year survival (%) year survival (%) CPT-11/Cis = irinotecan, 60 mg/m 2 i.v., days 1, 8, and 15; cisplatin, 80 mg/m 2 i.v., day 1 every 4 weeks. VDS/Cis = vindesine 3 mg/m 2 i.v., days 1, 8, and 15; cisplatin, 80 mg/m 2 i.v., day 1 every 4 weeks. CPT-11 = irinotecan, 100 mg/m 2 i.v., days 1, 8, and 15 every 4 weeks. Another phase III study compared irinotecan/cisplatin with vindesine/cisplatin and with irinotecan alone in stage IIIB/IV NSCLC patients (Table 12) [14]. Three hundred and ninety-eight patients were entered into the trial, 37% of whom had stage IIIB disease. For the above three arms, response rates were 43%, 31%, and 21%, respectively; median survival times were 50.3 weeks, 47.4 weeks, and 46.1 weeks, respectively; 1-year survival rates were 47.5%, 37.9%, and 40.7%, respectively; grade 4 neutropenia occurred in 36.2%, 53.2%, and 7.9% of patients, respectively, and grade 3 diarrhea was observed in 12.6%, 4.0%, and 15.0% of patients, respectively. Although the response rate was highest for the irinotecan/cisplatin combination, the survival times for all three regimens were similar. In the above two studies, when only data from patients with stage IV NSCLC were analyzed, the combination of irinotecan/cisplatin resulted in a median survival rate greater than or equal to that of vindesine/cisplatin in both studies [15]. In the irinotecan/cisplatin versus vindesine study the median survival times were 10.3 months and 10.4 months, respectively, and the 1- and 2-year survival rates were 36% versus 41% and 9% versus 10%, respectively. In the three-arm study comparing irinotecan/cisplatin with vindesine/cisplatin and with irinotecan alone, the median survival times were 11.5 months, 8.4 months, and 9.7 months, respectively. Both irinotecan arms had a statistically significant better survival time than did the vindesine/cisplatin arm. For the three regimens, the 1- and 2-year survival rates were 48%, 26%, and 37%, respectively, and 18%, 11%, and 21%, respectively. MOLECULAR AND BIOLOGIC TARGETED THERAPIES A number of small molecules have been developed to inhibit specific targets. They include angiogenesis inhibitors, epidermal growth factor receptor inhibitors, matrix metalloproteinase inhibitors, and HER 2/neu inhibitors. Phase I/II studies combining some of these agents (anti-vascular endothelial growth factor, OSI 774, ISIS 3521, Iressa, etc.) with chemotherapy to treat advanced NSCLC appear promising [16-19]. There is experimental evidence that cyclooxygenase-2 (COX-2) is overexpressed in the majority of NSCLC tumors, especially adenocarcinomas [20]. Because of this, studies are ongoing evaluating a selective COX-2 inhibitor, celecoxib, with chemotherapy in patients with NSCLC. A phase I/II trial of Iressa (ZD 1839), a tyrosine kinase inhibitor of epidermal growth factor receptor, to treat advanced NSCLC produced a 10% response rate [19]. There have been two randomized trials using either paclitaxel/carboplatin or gemcitabine/cisplatin compared with the same drugs with two different doses of Iressa as firstline therapy for advanced NSCLC (Fig. 1). These studies have closed and the data are being analyzed. Randomize *Gemcitabine/cisplatin or *Paclitaxel/carboplatin Chemotherapy* mg Iressa 6 cycles Chemotherapy* mg Iressa 6 cycles Chemotherapy* + placebo 6 cycles Primary end point: survival Continue Iressa or placebo until disease progression Figure 1. Iressa trials. First-line NSCLC.
7 Ettinger 232 DISCUSSION Is there a treatment of choice for patients with metastatic NSCLC? Or is there a choice of treatments for the cancer? In my opinion, there is a choice of treatments for NSCLC patients. No one regimen appears superior to another. This review included only phase III studies evaluating chemotherapy to treat patients with stage IIIB/IV NSCLC. The studies are from the U.S., Europe, and Japan. It is difficult to compare the data from the various studies for a variety of reasons, including different patient characteristics, patient selection criteria, etc. For example, those studies having greater than 30% of NSCLC patients with stage IIIB disease usually have higher response rates and better survival times than those studies having less than 20% of patients having stage IIIB NSCLC. There is still the question whether a noncisplatin-containing regimen is as good as or better than a cisplatin-containing regimen. The EORTC study showed that a paclitaxel/gemcitabine regimen had a lower median survival time and 1-year survival rate compared with a paclitaxel/cisplatin or gemcitabine/cisplatin regimen. However, there are not enough data to make the determination as to the effectiveness of noncisplatin-containing regimens REFERENCES 1 Jemal A, Thomas A, Murray T et al. Cancer statistics, CA Cancer J Clin 2002;52: Ginsberg KJ, Vokes EE, Rosenzweig K. Non small cell lung cancer. In: DeVita V, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Sixth Edition. Philadelphia: Lippincott Williams and Wilkins 2001: Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18: Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 1998;16: Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346: Kelly K, Crowley J, Bunn PA et al. A randomized phase III trial of paclitaxel + carboplatin (PC) versus vinorelbine + cisplatin (VC) in NSCLC: a Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 1999;18:461a. 7 Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000;18: versus cisplatin-containing regimens to treat advanced NSCLC. There are a number of combination chemotherapeutic regimens that can be used to treat advanced NSCLC. Most of these combinations are cisplatin based. The choice of the effective regimen to treat patients with NSCLC should be based on: Familiarity with the regimen Toxicity of the therapy Convenience of its administration Cost of the treatment Advanced NSCLC patients should be entered in clinical trials in order to improve the therapies. There is hope that, in the future, advances will be made in the treatment of patients with advanced NSCLC with the development of novel agents and with these agents used in combination with chemotherapeutic regimens. ACKNOWLEDGMENTS Presented in part at the Mayo Clinic s 11th Annual Hematology/Oncology Reviews, State-of-the-Art Treatment of Hematology/Oncology Treatments, Amelia Island, Florida, August 16-19, Cardenal F, Lopez-Cabrerizo MP, Anton A et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999;17: Kosmidis PA, Bacoyiannis C, Mylonakis N et al. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small cell lung cancer (NSCLC). Preliminary analysis. Proc Am Soc Clin Oncol 2000;19:488a. 10 Van Meerbeeck JP, Smit E, Lianes P et al. A EORTC randomized phase III trial of three chemotherapy regimen advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:308a. 11 Scagliotti GV, Dmarinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:308a. 12 Rodriquez J, Parvel J, Pluzanska A et al. A multicenter randomized phase III study of docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:314a. 13 Niho S, Nagao K, Nishiwaki Y et al. Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (DDP) versus CDDP and vindesine (VDS) in patients with advanced
8 233 Is There a Preferred Combination Chemotherapy Regimen for Metastastic NSCLC? non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999;18:492a. 14 Masuda N, Fukuoka M, Negoro S et al. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study. Proc Am Soc Clin Oncol 1999;18:459a. 15 Fukuoka M, Nagao K, Ohashi Y et al. Impact of irinotecan (CPT-11) and cisplatin (CDDP) on survival in previously untreated metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:495a. 16 Devore RT, Fehrenbacker I, Herbst RS et al. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000;19:485a. 17 Yuen A, Halsey J, Fisher G et al. Phase I/II trial of ISIS 3521 an antisense inhibitor of PKC-Alpha with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:309a. 18 Perez-Soler R, Chachoua A, Huberman M et al. A phase II trial of the EGFR tyrosine kinase inhibitor OSI-774 following platinum-based chemotherapy in patients with EGFR expressing NSCLC. Proc Am Soc Clin Oncol 2001;20:310a. 19 Ferry D, Hammond L, Ranson M et al. Intermittent oral ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, shows evidence of good tolerability and activity: final results from a phase I study. Proc Am Soc Clin Oncol 2000;19:3a. 20 Hida T, Kozaki K, Muramatsu H et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:
Oncologist. The. ASCO 2000: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. ABSTRACT
The Oncologist ASCO 2000: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Key Words. Small cell lung cancer Non-small
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationOncologist. The. Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review JAMES R. RIGAS LEARNING OBJECTIVES ABSTRACT
The Oncologist Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review JAMES R. RIGAS Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, USA Key Words.
More informationOncologist. The. Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer
The Oncologist Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer B.T. HENNESSY, a E.O. HANRAHAN, b O.S. BREATHNACH a,c a Department of Medical Oncology, Cork University
More informationSystemic chemotherapy improves both survival and quality
ORIGINAL ARTICLE Treatment of Elderly Non small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial Suresh Ramalingam,
More informationAuthor(s) Ohmatsu, Hironobu; Kubota, Kaoru; N. Citation Respiratory medicine (2010), 104(3)
Title Trends in chemotherapy for elderly non-small-cell lung cancer. Author(s) Kim, Young Hak; Yoh, Kiyotaka; Niho Ohmatsu, Hironobu; Kubota, Kaoru; N Citation Respiratory medicine (2010), 104(3) Issue
More informationSystemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Suresh Ramalingam, a Chandra Belani b a Lung & Thoracic Malignancies Program, University of Pittsburgh
More informationSCIENTIFIC DISCUSSION
London, 20 April 2005 Product name: PAXENE Procedure No. EMEA/H/C/399/II/26 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel:(44-20) 74 18 84, fax (44-20) 74 18 86 68 E-mail:
More informationOptimizing First-Line Treatment Options for Patients with Advanced NSCLC
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Optimizing First-Line Treatment Options for Patients with Advanced
More informationOncologist. The. ASCO 1999: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. The Oncologist 1999;4:
The Oncologist ASCO 1999: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital, Boston, Massachusetts, USA Adjuvant therapy does not work. Second-line therapy
More informationChemotherapy in Lung Cancer
Special Issue Chemotherapy in Lung Cancer Keunchil Park, M.D. Division of Hematology / Oncology, Department of Medicine Sungkyunkwan University School of Medicine, Samsung Medical Center E-mail : kpark@smc.samsung.co.kr
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationDavid S. Ettinger. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Lung Cancer Clinical Implications of EGFR Expression in the Development
More informationCâncer de Pulmão Não Pequenas Células
Câncer de Pulmão Não Pequenas Células Carboplatina + Paclitaxel Paclitaxel: 200mg/m 2 IV D1 Carboplatina: AUC 6 IV D1 a cada 21 dias X 4 ciclos Ref. (1) Vinorelbina + Cisplatina Vinorelbina: 25mg/m 2 IV
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationKey Words. Bevacizumab Avastin Nonsquamous Non-small cell lung cancer First-line Advanced/metastatic disease
The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Bevacizumab (Avastin ) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell
More informationLung cancer is the leading cause of cancer mortality in both
ORIGINAL ARTICLE Chemotherapy in Patients 80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and Paul J. Hesketh, MD,* Rogerio C. Lilenbaum, MD, Kari Chansky, MS, Afshin Dowlati,
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationLung cancer is the leading cause of cancer death in the
ORIGINAL ARTICLE A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly Yuh-Min Chen, MD, PhD,* Reury-Perng Perng,
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationThe effect of EGFR overexpression in inoperable non-small cell lung cancer (NSCLC) patients receiving cisplatinvinorelbine
Turkish Journal of Cancer Volume 36, No.1, 2006 11 The effect of EGFR overexpression in inoperable non-small cell lung cancer (NSCLC) patients receiving cisplatinvinorelbine combination MAHMOUD A. SALAM
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationYuh-Min Chen, MD, PhD; Reury-Perng Perng, MD, PhD; Jen-Fu Shih, MD; Chun-Ming Tsai, MD; and Jacqueline Whang-Peng, MD
Chemotherapy for Non-small Cell Lung Cancer in Elderly * Yuh-Min Chen, MD, PhD; Reury-Perng Perng, MD, PhD; Jen-Fu Shih, MD; Chun-Ming Tsai, MD; and Jacqueline Whang-Peng, MD Study objective: To determine
More informationPart 7 of a 12-Part Series
Release Date: June 1, 2003. Publication Date, Part 7: September 1, 2003. Termination Date: December 31, 2004. Estimated time to complete this 12-part newsletter series: 3.0 hours. Each newsletter in this
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationBevacizumab treatment for advanced non small cell lung cancer: A case report
ONCOLOGY LETTERS 6: 1779-1783, 2013 Bevacizumab treatment for advanced non small cell lung cancer: A case report YUN FAN *, ZHIYU HUANG and WEIMIN MAO * Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationNon-small cell lung cancer (NSCLC) accounts for 80% of
ORIGINAL ARTICLE Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience Athanasios G.
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationLung cancer remains the leading cause of cancer-related
ORIGINAL ARTICLE Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis Maria Q. Baggstrom, MD,* Thomas E. Stinchcombe, MD, Daniel B. Fried, MD, PhD,
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationPhase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
Original article Annals of Oncology 13: 1862 1867, 2002 DOI: 10.1093/annonc/mdf308 Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer V.
More informationPlatinum-based doublets are considered to be the standard
Blackwell Publishing Asia Review Article Recent trends in the treatment of advanced lung cancer Nagahiro Saijo 1 National Cancer Center, Hospital East, Kashiwanoha 6-5-1, Kashiwa-shi, Chiba 277-8577, Japan
More informationThree-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study
Original article Annals of Oncology 13: 1080 1086, 2002 DOI: 10.1093/annonc/mdf186 Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study H. Soto Parra
More informationClinical PATIENTS AND METHODS. Patients
British Journal of Cancer (2004) 90, 87 92 All rights reserved 0007 0920/04 $25.00 www.bjcancer.com Randomised phase II study of docetaxel/cisplatin vs docetaxel/ irinotecan in advanced non-small-cell
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationGemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
Clinical Medicine Insights: Oncology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationThe New England Journal of Medicine COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON SMALL-CELL LUNG CANCER
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON SMALL-CELL LUNG CANCER JOAN H. SCHILLER, M.D., DAVID HARRINGTON, PH.D., CHANDRA P. BELANI, M.D., COREY LANGER, M.D., ALAN SANDLER, M.D., JAMES
More informationFirst line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger
More informationdoi: /theoncologist originally published online February 3, 2009
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line? Cesare Gridelli, Paolo Maione, Antonio Rossi, Marianna Luciana Ferrara, Maria Anna
More informationSmall cell lung cancer (SCLC) accounts for approximately
ORIGINAL ARTICLE A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer Jingwei
More informationGUODONG SHEN 1,2, GENG BIAN 2, HAIYING YU 2, MIN GAO 1, DONGMEI KANG 1, GAN SHEN 1,2 and SHILIAN HU 1,2
146 Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non small cell lung cancer: A meta analysis of randomized controlled trials GUODONG SHEN 1,2,
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationAHFS Final. line. Criteria Used in. combined. cisplatin. Strength. established was. Non-small Cell Lung. Cancer: of carboplatin and
Drug/Drug Combination: Cetuximab Off-label Use: First-line treatment of advanced non-small Use for Review: cell lung cancer Criteria Used in Selection of Off-labell AHFS Final Determination of Medical
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationONCOLOGY LETTERS 5: , 2013
ONCOLOGY LETTERS 5: 761-767, 2013 Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer TOSHIKI
More informationThe management of patients with advanced non-small cell
ORIGINAL ARTICLE Gemcitabine versus Gemcitabine Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationPaclitaxel in Breast Cancer
Paclitaxel in Breast Cancer EDITH A. PEREZ Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, USA Key Words. Paclitaxel Antineoplastic agents Breast neoplasms Clinical trials ABSTRACT
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationEDITH A. PEREZ. Multidisciplinary Breast Clinic, Mayo Clinic and Mayo Foundation, Jacksonville, Florida, USA
The Oncologist Breast Cancer Carboplatin in Combination Therapy for Metastatic Breast Cancer EDITH A. PEREZ Multidisciplinary Breast Clinic, Mayo Clinic and Mayo Foundation, Jacksonville, Florida, USA
More informationRegulatory Issues - FDA
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Regulatory Issues - FDA FDA Drug Approval Summary: Erlotinib
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationKey Words. FDA summary Metastatic breast cancer Multidrug resistant Lapatinib Capecitabine
The Oncologist Regulatory Issues FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2 QIN RYAN, AMNA IBRAHIM, MARTIN
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationLarge-cell neuroendocrine carcinoma (LCNEC) and
BRIEF REPORT Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung A Multicenter Phase II Study Seiji Niho, MD, PhD,* Hirotsugu Kenmotsu, MD, Ikuo Sekine,
More informationKeywords: cohort study, chemotherapy, survival rate, elderly, patient selection, outcome
Treatment of Advanced Non Small Cell Lung Cancer in Routine Care: A Retrospective Analysis of 212 Consecutive Patients Treated in a Community Based Oncology Group Practice ORIGINAL RESEARCH Hubert Koeppler
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationA Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study
J Lung Cancer 2007;6(1):1-7 A Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study Purpose: Since the combination of cisplatin plus
More informationTargeting NSCLC: Despite being the most preventable of all. Update On a New Therapy. Robert s case
Focus on CME at the University of Calgary Targeting NSCLC: Update On a New Therapy Cynthia M. Card, MD, FRCPC Presented at the University of Calgary s Evening Lecture Series, January 2003 Despite being
More informationGenitourinary Cancer. The Role of Taxanes in the Management of Bladder Cancer. The Oncologist 2005;10: Matthew D.
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Genitourinary Cancer The Role of Taxanes in the Management of
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationThe Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(4):638-644 Original Article http://dx.doi.org/10.4143/crt.2014.316 Open Access The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationLung cancer represents a significant cause of morbidity and
STATE OF THE ART: CONCISE REVIEW Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer Pablo M. Bedano, MD, and Nasser H. Hanna, MD Patients with advanced non-small cell lung cancer continue
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationSurvival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationPhase II Study of Carboplatin Paclitaxel Combination Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung Cancer
Phase II Study of Carboplatin Paclitaxel Combination Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung Cancer Isamu Okamoto 1,2, Eiji Moriyama 1, Shinji Fujii 1, Hiroto Kishi 1, Masanobu
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationLung cancer remains the leading cause of cancer-related
ORIGINAL ARTICLE Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer Cancer and Leukemia Group B Study 39901 Stephen L. Graziano, MD,* James E. Herndon, II, PhD, Mark
More informationKey Words. Epidermal growth factor receptor EGFR Tyrosine kinase inhibitor TKI Erlotinib Non-small cell lung cancer NSCLC Second-line therapy
The Oncologist Lung Cancer Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance? THOMAS E. STINCHCOMBE,MARK A. SOCINSKI Multidisciplinary Thoracic Oncology Program, Lineberger
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationSystemic chemotherapy plays an important role in the
ORIGINAL ARTICLE Tegafur-Uracil Plus Gemcitabine Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Platinum Takashi Seto, MD,* Takeharu Yamanaka, PhD,
More informationRandomized Phase II Study of Two Different Schedules of Gemcitabine and Oral S-1 in Chemo-naïve Patients with Advanced Non-small Cell Lung Cancer
ORIGINAL ARTICLE Randomized Phase II Study of Two Different Schedules of Gemcitabine and Oral S-1 in Chemo-naïve Patients with Advanced Non-small Cell Lung Cancer Miyako Satouchi, MD,* Yoshikazu Kotani,
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationCetuximab in non-small-cell lung cancer
Review Article Cetuximab in non-small-cell lung cancer Robert Pirker, Martin Filipits Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria Corresponding to: Robert Pirker, MD. Department
More information